Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

Published:2015-04-02 Issue:7 Volume:9 Page:1371-1383
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:

Author:

Stanam Aditya,Love-Homan Laurie,Joseph Tisha S.,Espinosa-Cotton Madelyn,Simons Andrean L.

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1016/j.molonc.2015.03.008/fullpdf

Reference23 articles.

1. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck;Argiris;Ann. Oncol.,2013

2. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients;Bei;J. Pathol.,2004

3. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck;Cohen;Clin. Cancer Res.,2005

4. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck;de Souza;Clin. Cancer Res.,2012

5. Interleukin-6 predicts recurrence and survival among head and neck cancer patients;Duffy;Cancer,2008

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mononuclear phagocyte system-related multi-omics features yield head and neck squamous cell carcinoma subtypes with distinct overall survival, drug, and immunotherapy responses;Journal of Cancer Research and Clinical Oncology;2024-01-27

2. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics;Cancers;2024-01-24

3. Interleukin-6 in Hepatocellular Carcinoma: A Dualistic Point of View;Biomedicines;2023-09-24

4. Cancer-associated fibroblasts: Mediators of head and neck tumor microenvironment remodeling;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-09

5. Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition;International Journal of Molecular Sciences;2023-03-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3